References
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82; PMID:3798106; http://dx.doi.org/10.1126/science.3798106
- Fiszman GL, Jasnis MA. Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer. Int J Breast Cancer 2011; 2011:352182; PMID:22295219; http://dx.doi.org/10.4061/2011/352182
- Beano A, Signorino E, Evangelista A, Brusa D, Mistrangelo M, Polimeni MA, Spadi R, Donadio M, Ciuffreda L, Matera L. Correlation between NK function and response to trastuzumab in metastatic breast cancer patients. J Transl Med 2008; 6:25, 5876-6-25; PMID:18485193; http://dx.doi.org/10.1186/1479-5876-6-25
- Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol 2011; 2011:379123; PMID:21660134; http://dx.doi.org/10.1155/2011/379123
- Beurskens FJ, Lindorfer MA, Farooqui M, Beum PV, Engelberts P, Mackus WJ, Parren PW, Wiestner A, Taylor RP. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012; 188:3532-41; PMID:22368276; http://dx.doi.org/10.4049/jimmunol.1103693
- Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, Muchhal U, Desjarlais JR, Humpe A, Valerius T, Peipp M. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity. mAbs 2014; 6:409-21; PMID:24492248; http://dx.doi.org/10.4161/mabs.27457
- Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704
- Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25:3712-8; PMID:17704420; http://dx.doi.org/10.1200/JCO.2006.08.8021
- Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:1789-96; PMID:18347005; http://dx.doi.org/10.1200/JCO.2007.14.8957
- Senior BW, Woof JM. The influences of hinge length and composition on the susceptibility of human IgA to cleavage by diverse bacterial IgA1 proteases. J Immunol 2005; 174:7792-9; PMID:15944283; http://dx.doi.org/10.4049/jimmunol.174.12.7792
- Morton HC, van Egmond M, van de Winkel JG. Structure and function of human IgA fc receptors (fc α R). Crit Rev Immunol 1996; 16:423-40; PMID:8954257
- Gregory AD, Houghton AM. Tumor-associated neutrophils: New targets for cancer therapy. Cancer Res 2011; 71:2411-6; PMID:21427354; http://dx.doi.org/10.1158/0008-5472.CAN-10-2583
- Lohse S, Brunke C, Derer S, Peipp M, Boross P, Kellner C, Beyer T, Dechant M, van der Winkel JG, Leusen JH, et al. Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. J Biol Chem 2012; 287:25139-50; PMID:22679018; http://dx.doi.org/10.1074/jbc.M112.353060
- Boross P, Lohse S, Nederend M, Jansen JH, van Tetering G, Dechant M, Peipp M, Royle L, Liew LP, Boon L, et al. IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med 2013; 5:1213-26; PMID:23918228; http://dx.doi.org/10.1002/emmm.201201929
- Kelton W, Mehta N, Charab W, Lee J, Lee CH, Kojima T, Kang TH, Georgiou G. IgGA: A “cross-isotype” engineered human fc antibody domain that displays both IgG-like and IgA-like effector functions. Chem Biol 2014; 21:1603-9; PMID:25500223; http://dx.doi.org/10.1016/j.chembiol.2014.10.017
- Pascal V, Laffleur B, Debin A, Cuvillier A, van Egmond M, Drocourt D, Imbertie L, Pangault C, Tarte K, Tiraby G, et al. Anti-CD20 IgA can protect mice against lymphoma development: Evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. Haematologica 2012; 97:1686-94; PMID:22689689; http://dx.doi.org/10.3324/haematol.2011.061408
- Stockert RJ, Kressner MS, Collins JC, Sternlieb I, Morell AG. IgA interaction with the asialoglycoprotein receptor. Proc Natl Acad Sci U S A 1982; 79:6229-31; PMID:6292896; http://dx.doi.org/10.1073/pnas.79.20.6229
- Rouwendal GJA, van der Lee MM, Meyer S, Reiding KR, Schouten J, de Roo G, Egging DF, Leusen JHW, Boross P, Wuhrer M, et al. A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA. mAbs 2016; http://dx.doi.org/10.1080/19420862.2015.1102812
- Story CM, Mikulska JE, Simister NE. A major histocompatibility complex class I-like fc receptor cloned from human placenta: Possible role in transfer of immunoglobulin G from mother to fetus. J Exp Med 1994; 180:2377-81; PMID:7964511; http://dx.doi.org/10.1084/jem.180.6.2377
- Firan M, Bawdon R, Radu C, Ober RJ, Eaken D, Antohe F, Ghetie V, Ward ES. The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans. Int Immunol 2001; 13:993-1002; PMID:11470769; http://dx.doi.org/10.1093/intimm/13.8.993
- Vidarsson G, Stemerding AM, Stapleton NM, Spliethoff SE, Janssen H, Rebers FE, de Haas M, van de Winkel JG. FcRn: An IgG receptor on phagocytes with a novel role in phagocytosis. Blood 2006; 108:3573-9; PMID:16849638; http://dx.doi.org/10.1182/blood-2006-05-024539
- Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, Blumberg RS, Lencer WI. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 1999; 104:903-11; PMID:10510331; http://dx.doi.org/10.1172/JCI6968
- Zhu X, Meng G, Dickinson BL, Li X, Mizoguchi E, Miao L, Wang Y, Robert C, Wu B, Smith PD, et al. MHC class I-related neonatal fc receptor for IgG is functionally expressed in monocytes, intestinal macrophages, and dendritic cells. J Immunol 2001; 166:3266-76; PMID:11207281; http://dx.doi.org/10.4049/jimmunol.166.5.3266
- Ghetie V, Ward ES. Transcytosis and catabolism of antibody. Immunol Res 2002; 25:97-113; PMID:11999172; http://dx.doi.org/10.1385/IR:25:2:097
- Goebl NA, Babbey CM, Datta-Mannan A, Witcher DR, Wroblewski VJ, Dunn KW. Neonatal fc receptor mediates internalization of fc in transfected human endothelial cells. Mol Biol Cell 2008; 19:5490-505; PMID:18843053; http://dx.doi.org/10.1091/mbc.E07-02-0101
- Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest 1970; 49:673-80; PMID:5443170; http://dx.doi.org/10.1172/JCI106279
- Vieira P, Rajewsky K. The half-lives of serum immunoglobulins in adult mice. Eur J Immunol 1988; 18:313-6; PMID:3350037; http://dx.doi.org/10.1002/eji.1830180221
- Montoyo HP, Vaccaro C, Hafner M, Ober RJ, Mueller W, Ward ES. Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice. Proc Natl Acad Sci U S A 2009; 106:2788-93; PMID:19188594; http://dx.doi.org/10.1073/pnas.0810796106
- Peters T Jr. Serum albumin. Adv Protein Chem 1985; 37:161-245; PMID:3904348; http://dx.doi.org/10.1016/S0065-3233(08)60065-0
- Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. Increased clearance of IgG in mice that lack β 2-microglobulin: Possible protective role of FcRn. Immunology 1996; 89:573-8; PMID:9014824; http://dx.doi.org/10.1046/j.1365-2567.1996.d01-775.x
- Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, Ward ES. Abnormally short serum half-lives of IgG in β 2-microglobulin-deficient mice. Eur J Immunol 1996; 26:690-6; PMID:8605939; http://dx.doi.org/10.1002/eji.1830260327
- Jonsson A, Dogan J, Herne N, Abrahmsen L, Nygren PA. Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng Des Sel 2008; 21:515-27; PMID:18499681; http://dx.doi.org/10.1093/protein/gzn028
- Hopp J, Hornig N, Zettlitz KA, Schwarz A, Fuss N, Muller D, Kontermann RE. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. Protein Eng Des Sel 2010; 23:827-34; PMID:20817756; http://dx.doi.org/10.1093/protein/gzq058
- Stork R, Muller D, Kontermann RE. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng Des Sel 2007; 20:569-76; PMID:17982179; http://dx.doi.org/10.1093/protein/gzm061
- Andersen JT, Pehrson R, Tolmachev V, Daba MB, Abrahmsen L, Ekblad C. Extending half-life by indirect targeting of the neonatal fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem 2011; 286:5234-41; PMID:21138843; http://dx.doi.org/10.1074/jbc.M110.164848
- Malm M, Bass T, Gudmundsdotter L, Lord M, Frejd FY, Stahl S, Lofblom J. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension. Biotechnol J 2014; 9:1215-22; PMID:24678002; http://dx.doi.org/10.1002/biot.201400009
- Reiding KR, Blank D, Kuijper DM, Deelder AM, Wuhrer M. High-throughput profiling of protein N-glycosylation by MALDI-TOF-MS employing linkage-specific sialic acid esterification. Anal Chem 2014; 86:5784-93; PMID:24831253; http://dx.doi.org/10.1021/ac500335t
- Peters T Jr. All about Albumin: Biochemistry, Genetics and Medical Applications. San Diego, CA, USA: Elsevier Academic Press, 1996.
- Wolfe-Coote S, ed. The Handbook of Experimental Animals: The Laboratory Primate. San Diego, CA, USA: Elsevier Academic Press; 2005.
- Wang H, Niu YY, Si W, Li YJ, Yan Y. Reference data of clinical chemistry, haematology and blood coagulation parameters in juvenile cynomolgus monkeys (macaca fascicularis). Veterinarni Medicina 2012; 57:233-8.
- Dechant M, Beyer T, Schneider-Merck T, Weisner W, Peipp M, van de Winkel JG, Valerius T. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol 2007; 179:2936-43; PMID:17709508; http://dx.doi.org/10.4049/jimmunol.179.5.2936
- Gomes MM, Wall SB, Takahashi K, Novak J, Renfrow MB, Herr AB. Analysis of IgA1 N-glycosylation and its contribution to FcalphaRI binding. Biochemistry 2008; 47:11285-99; PMID:18826328; http://dx.doi.org/10.1021/bi801185b
- Stork R, Campigna E, Robert B, Muller D, Kontermann RE. Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem 2009; 284:25612-9; PMID:19628871; http://dx.doi.org/10.1074/jbc.M109.027078
- Rifai A, Fadden K, Morrison SL, Chintalacharuvu KR. The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulin (ig)A1 and IgA2 isotypes. J Exp Med 2000; 191:2171-82; PMID:10859341; http://dx.doi.org/10.1084/jem.191.12.2171
- Baenziger J, Kornfeld S. Structure of the carbohydrate units of IgA1 immunoglobulin. I. composition, glycopeptide isolation, and structure of the asparagine-linked oligosaccharide units. J Biol Chem 1974; 249:7260-9; PMID:4436308
- Endo T, Mestecky J, Kulhavy R, Kobata A. Carbohydrate heterogeneity of human myeloma proteins of the IgA1 and IgA2 subclasses. Mol Immunol 1994; 31:1415-22; PMID:7823967; http://dx.doi.org/10.1016/0161-5890(94)90157-0
- Field MC, Amatayakul-Chantler S, Rademacher TW, Rudd PM, Dwek RA. Structural analysis of the N-glycans from human immunoglobulin A1: Comparison of normal human serum immunoglobulin A1 with that isolated from patients with rheumatoid arthritis. Biochem J 1994; 299 ( Pt 1):261-75; PMID:8166649; http://dx.doi.org/10.1042/bj2990261
- Mattu TS, Pleass RJ, Willis AC, Kilian M, Wormald MR, Lellouch AC, Rudd PM, Woof JM, Dwek RA. The glycosylation and structure of human serum IgA1, fab, and fc regions and the role of N-glycosylation on fcalpha receptor interactions. J Biol Chem 1998; 273:2260-72; PMID:9442070; http://dx.doi.org/10.1074/jbc.273.4.2260
- Oortwijn BD, Roos A, Royle L, van Gijlswijk-Janssen DJ, Faber-Krol MC, Eijgenraam JW, Dwek RA, Daha MR, Rudd PM, van Kooten C. Differential glycosylation of polymeric and monomeric IgA: A possible role in glomerular inflammation in IgA nephropathy. J Am Soc Nephrol 2006; 17:3529-39; PMID:17050773; http://dx.doi.org/10.1681/ASN.2006040388
- Raju TS, Briggs JB, Borge SM, Jones AJ. Species-specific variation in glycosylation of IgG: Evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000; 10:477-86; PMID:10764836; http://dx.doi.org/10.1093/glycob/10.5.477
- Zhou J, Mateos F, Ober RJ, Ward ES. Conferring the binding properties of the mouse MHC class I-related receptor, FcRn, onto the human ortholog by sequential rounds of site-directed mutagenesis. J Mol Biol 2005; 345:1071-81; PMID:15644205; http://dx.doi.org/10.1016/j.jmb.2004.11.014
- Andersen JT, Daba MB, Berntzen G, Michaelsen TE, Sandlie I. Cross-species binding analyses of mouse and human neonatal fc receptor show dramatic differences in immunoglobulin G and albumin binding. J Biol Chem 2010; 285:4826-36; PMID:20018855; http://dx.doi.org/10.1074/jbc.M109.081828
- Morell A, Skvaril F, Noseda G, Barandun S. Metabolic properties of human IgA subclasses. Clin Exp Immunol 1973; 13:521-8; PMID:4717094
- Mezo AR, McDonnell KA, Hehir CA, Low SC, Palombella VJ, Stattel JM, Kamphaus GD, Fraley C, Zhang Y, Dumont JA, et al. Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal fc receptor FcRn. Proc Natl Acad Sci U S A 2008; 105:2337-42; PMID:18272495; http://dx.doi.org/10.1073/pnas.0708960105
- Seijsing J, Lindborg M, Hoiden-Guthenberg I, Bonisch H, Guneriusson E, Frejd FY, Abrahmsen L, Ekblad C, Lofblom J, Uhlen M, et al. An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein. Proc Natl Acad Sci U S A 2014; 111:17110-5; PMID:25406323; http://dx.doi.org/10.1073/pnas.1417717111
- Sockolosky JT, Tiffany MR, Szoka FC. Engineering neonatal fc receptor-mediated recycling and transcytosis in recombinant proteins by short terminal peptide extensions. Proc Natl Acad Sci U S A 2012; 109:16095-100; PMID:22991460; http://dx.doi.org/10.1073/pnas.1208857109
- Frejd FY. Half-life extension by binding to albumin through an albumin binding domain. In: Kontermann R, ed. Therapeutic Proteins: Strategies to Modulate their Plasma Half-Lives. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2012:269.
- Roopenian DC, Low BE, Christianson GJ, Proetzel G, Sproule TJ, Wiles MV. Albumin-deficient mouse models for studying metabolism of human albumin and pharmacokinetics of albumin-based drugs. mAbs 2015; 7:344-51; PMID:25654695; http://dx.doi.org/10.1080/19420862.2015.1008345
- van Egmond M, van Vuuren AJ, Morton HC, van Spriel AB, Shen L, Hofhuis FM, Saito T, Mayadas TN, Verbeek JS, van de Winkel JG. Human immunoglobulin A receptor (FcalphaRI, CD89) function in transgenic mice requires both FcR gamma chain and CR3 (CD11b/CD18). Blood 1999; 93:4387-94; PMID:10361137/